课题基金 / 基金详情

Regulatory Mechanisms Addressing Diabetic Vasculopathy

Regulatory Mechanisms Addressing Diabetic Vasculopathy
解决糖尿病血管病变的调节机制
批准号:
10718850
负责人:
Kanhaiya Singh
金额:
$38.25万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-07 至 2028-06-30
关键词:
AccountingAddressAdjuvantAdultAffectAngioblastBlood VesselsCDH5 geneCadherinsCardiovascular systemCell CompartmentationCellsClinicalClinical ResearchClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsComplexCpG IslandsCyclic AMP-Dependent Protein KinasesDNADNA MethylationDermalDevelopmentDiabetes MellitusDiglyceridesDinoprostoneDown-RegulationEicosanoidsElementsEndothelial CellsEndotheliumEnvironmentEpigenetic ProcessExhibitsGene CombinationsGene ExpressionGene TargetingGenerationsGenesGranulation TissueGuide RNAHealthcareHumanHyperglycemiaHypermethylationInfectionInjuryInositolIschemiaKnockout MiceLiteratureMacrophageMediatingMedicareMethylationMolecularMusMyelogenousMyeloid CellsNon-Insulin-Dependent Diabetes MellitusObesityOutcomeOutcome StudyPIK3CG genePLCgamma2Pathway interactionsPatientsPerfusionPhosphatidic AcidPopulationPrevalenceProcessProductionProtein DephosphorylationProto-Oncogene Proteins c-aktReactive Oxygen SpeciesRecovery of FunctionRegimenRegulationReportingResearchRoleSignal PathwaySignal TransductionSkinTREM2 geneTestingTherapeuticTherapeutic InterventionTissuesVascular DiseasesVascular Endothelial Growth FactorsVascularizationWorkaging populationangiogenesisbeneficiaryblood vessel developmentcadherin 5chronic woundcombination gene therapycostdemethylationdiabeticdiabetic ulcerdiabetic wound healingepigenetic silencingexpectationfallsfunctional outcomesimprovedin vivoinjuredlipid mediatorlymphatic vesselnon-diabeticpreventpromoterpublic health relevancesingle-cell RNA sequencingtherapy outcometooltripolyphosphatevasculogenesiswoundwound healingwound vascularization

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
摘要
英文摘要
ABSTRACT The prevalence of diabetes, obesity, and vascular disease in an aging population is fueling a surge in chronic skin wounds, which affect >8 million Medicare beneficiaries at a cost of >$96 billion per year. An estimated 2.5% of US population is affected by chronic wounds. Diabetic ulcers (DU), complicated by infection/ischemia/high reactive oxygen species, often suffer from poor perfusion. Reliance on VEGF therapy to improve perfusion makes logical sense, yet clinical study outcomes fall far short of expectations. Possible factors limiting VEGF therapy outcomes include insufficient local concentration of VEGF signaling partners and regression of immature vessels. It is critically important to troubleshoot barriers and to establish a therapeutic regimen that delivers desirable functional outcomes. To circumvent the low-efficiency hurdle of VEGF single-gene “monotherapy”, development of “combined gene therapy” was initiated to deliver of two or more angiogenic molecules to substantially enhance efficacy. Current literature presents compelling evidence recognizing a critical role of active lipid mediators such as eicosanoids in enabling VEGF-dependent angiogenesis. However, the implementation of VEGF therapy has not tested the significance of these lipid mediators as necessary adjuvant. Recently we have reported that in diabetic ischemic skin endothelial cells, PLCγ2 levels remain low accounting for diminished efficiency of VEGF therapy. However, the underlying mechanisms of such downregulation remain unknown. Emerging evidence demonstrate that hyperglycemia leads to DNA methylation and epigenetic silencing in the complex interplay between genes and the environment in DU subjects. In addition to endothelium, PLCγ2 enables macrophage function via TREM2 signaling. TREM2+ macrophages participate in tissue angiogenesis post-injury. The central hypothesis is that hyperglycemia dependent loss of vascular PLCγ2– myeloid TREM2 crosstalk compromises VEGF-induced increase in diabetic wound-edge vascularization. Gene targeted DNA demethylation has potential to rescue PLCγ2 gene expression. The proposed line of work is the first to study CRISPR/dCas9-based in vivo targeted epigenetic editing of dermal endothelial cells as a therapeutic intervention for enabling VEGF therapy. Three aims are proposed: Aim 1. Determine the epigenetic mechanisms underlying PLCγ2 regulation of VEGF signaling under hyperglycemic conditions. Aim 2. Elucidate the molecular mechanisms by which PLCγ2 regulates wound tissue vascularization. Aim 3. Evaluate the functional significance of endothelial-targeted PLCγ2 augmentation in vascular-myeloid crosstalk as it relates to diabetic wound vascularization. The proposed research will unveil the critical role of PLCγ2 and the impact of this important element in VEGF signaling to help improve the efficiency and robustness of vasculogenic VEGF therapy in diabetic wound healing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金